title: A feasibility study of a 3-day basal-bolus insulin delivery device in individuals with type 2 diabetes.
abstract: OBJECTIVE
  This study tested the feasibility of transition from multiple daily injections (MDI) to a 3-day, basal-bolus insulin delivery device (PaQ) for type 2 diabetes (T2D).
  
  
  METHODS
  Twenty MDI-treated individuals with T2D with HbA(1c) ≤9% (75 mmol/mol) were enrolled in a single-center, single-arm pilot study, lasting three 2-week periods: baseline (MDI), transition to PaQ, and PaQ therapy. Feasibility of use, glycemic control, safety, and patient satisfaction were assessed.
  
  
  RESULTS
  Nineteen participants transitioned to PaQ treatment and demonstrated competency in assembling, placing, and using the device. Self-monitored blood glucose and blinded continuous glucose-monitoring data showed glycemic control similar to MDI. Study participants reported high satisfaction and device acceptance.
  
  
  CONCLUSIONS
  PaQ treatment is both feasible and acceptable in individuals with T2D. Transition from MDI is easy and safe. PaQ treatment might lead to better therapy adherence and improvements in glycemic control and clinical outcomes.
authors.affiliation: Corresponding author: Thomas R. Pieber, thomas.pieber@medunigraz.at.
authors.forename: Julia K
authors.initials: JK
authors.lastname: Mader
authors.forename: Leslie C
authors.initials: LC
authors.lastname: Lilly
authors.forename: Felix
authors.initials: F
authors.lastname: Aberer
authors.forename: Stefan
authors.initials: S
authors.lastname: Korsatko
authors.forename: Ellie
authors.initials: E
authors.lastname: Strock
authors.forename: Roger S
authors.initials: RS
authors.lastname: Mazze
authors.forename: Peter
authors.initials: P
authors.lastname: Damsbo
authors.forename: Thomas R
authors.initials: TR
authors.lastname: Pieber
mesh_terms: D000328:Adult; D000368:Aged; D001786:Blood Glucose / Q000032:analysis; D003924:Diabetes Mellitus, Type 2 / Q000188:drug therapy*; D004334:Drug Administration Schedule; D005240:Feasibility Studies; D005260:Female; D006801:Humans; D007004:Hypoglycemic Agents / Q000008:administration & dosage*; D007328:Insulin / Q000008:administration & dosage*; D007332:Insulin Infusion Systems; D008297:Male; D008875:Middle Aged; D017060:Patient Satisfaction; D010865:Pilot Projects
chemical_list: D001786:Blood Glucose; D007004:Hypoglycemic Agents; D007328:Insulin